EP300 and prostate cancer: Dihydrotestosterone causes acetylation of the androgen receptor (AR), and HDACi increase p300 binding while reducing N-CoR/HDAC/Smad3 co-repressor binding, improving cell survival and growth in prostate cancer cells both in vivo and in vitro (Fu et al., 2003).